News from Thursday, February 13, 2025
Articles
Balancing the New Trend in HEOR Organizational Structure and Focus
(2/13, John Graham, PharmD and Ross Maclean, MD, PharmExec) comments “...To be successful, HEOR requires executive leaders who have both scientific and managerial acumen; including a deep understanding of the multiple different methods that the discipline applies to generate evidence, the management skills to navigate complex, matrixed organizations, and the ability to distill complex strategic challenges at disease- and product-level and translate that to inform tangible tactics and value messages that may be delivered by multiple stakeholders in the market. Yet in many instances, the HEOR discipline and corresponding leadership has merged with other functional domains.” Full
Montana Looks To Regulate Prior Authorization as Patients, Providers Decry Obstacles to Care
(2/13, Mike Dennison, KFF Health News) reports “...Many of the state’s medical providers are behind the effort, saying prior authorization is denying vital care and needlessly sucking up more and more of their time, which they say could be better spent with patients...Montana health insurers, however, insist they are authorizing drugs and treatments that are shown to be needed. If their review power is stripped away, costs will continue to increase due to insurance paying for unnecessary treatments, they said.” Full
Third Way Floats 340B Reforms Spurred By New Analysis
(2/12, Gabrielle Wanneh, Inside Health Policy) reports “...The public policy think tank Third Way calls for Congress to reform the 340B drug discount program by restricting how much safety net hospitals can charge for outpatient prescription drugs and preventing the misuse of consolidation practices by participating 340B facilities in an analysis out Wednesday (Feb. 12).” Subscription Required
Brazil Consults On How To Price Advanced Therapies
(2/13, Francesca Bruce, Pink Sheet) reports “...The committee that regulates medicine pricing in Brazil, CMED, is seeking feedback from the public on its plan to create specific pricing regulations for advanced therapy medicinal products (ATMPs). The medicines regulator, ANVISA, hopes an appropriate pricing framework for advanced therapies will drive sustainable access to these medicines.” Subscription Required
Press Releases
Truveta Data Expands Beyond EHR Data with Linked Closed Claims for More than 200 Million Patients
(2/13, Truveta Press Release) “Today, Truveta announced the expansion of Truveta Data with the addition of new commercial, Medicare, and Medicaid closed claims on more than 200 million patients, linked with electronic health record (EHR) data for more than 120 million patients already part of Truveta Data. Truveta Data now provides researchers with the most complete view of the longitudinal patient journey, supporting regulatory grade health economics and outcomes research (HEOR), safety monitoring, and comparative effectiveness studies. By linking complete clinical data with comprehensive claims records, Truveta advances real-world evidence (RWE) generation that can replace, or complement, clinical trials and registries.” Full